{"transactions":[{"id":679711,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-21T00:05:06.000Z","date":"2026-08-19","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on March 3, 2025 and vests in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":114072,"derivative":{"exercise_price":14.41,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-26-359636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526359636/ownership.xml","form_type":"4"}},{"id":679710,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-21T00:05:06.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":24.5,"value":245000.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-359636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526359636/ownership.xml","form_type":"4"}},{"id":679709,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-21T00:05:06.000Z","date":"2026-08-19","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":14.41,"value":144100.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001193125-26-359636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526359636/ownership.xml","form_type":"4"}},{"id":679708,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-21T00:05:06.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":4212,"price":24.5,"value":103194.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares sold include 718 shares previously acquired by the reporting person pursuant to the Viridian Therapeutics, Inc. Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-359636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526359636/ownership.xml","form_type":"4"}},{"id":853108,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-09T23:35:29.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":1675,"price":30.19,"value":50568.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4."}],"balance_after":3494,"source":{"system":"sec-edgar","filing":"0001193125-26-099008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526099008/ownership.xml","form_type":"4/A","original_submission_date":"2026-03-04"}},{"id":860716,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-05T00:17:16.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":5169,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":15510,"derivative":{"underlying":"Common Stock","underlying_shares":5169},"source":{"system":"sec-edgar","filing":"0001193125-26-092074","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092074/ownership.xml","form_type":"4"}},{"id":860715,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-05T00:17:16.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":23850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":23850,"derivative":{"underlying":"Common Stock","underlying_shares":23850},"source":{"system":"sec-edgar","filing":"0001193125-26-092074","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092074/ownership.xml","form_type":"4"}},{"id":860714,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-05T00:17:16.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":119300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.  The date of the grant is March 2, 2026."}],"balance_after":119300,"derivative":{"exercise_price":30.25,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":119300},"source":{"system":"sec-edgar","filing":"0001193125-26-092074","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092074/ownership.xml","form_type":"4"}},{"id":860713,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:17:16.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":1724,"price":29.32,"value":50547.68,"ownership":{"direct":true},"balance_after":3445,"source":{"system":"sec-edgar","filing":"0001193125-26-092074","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092074/ownership.xml","form_type":"4"}},{"id":860712,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:17:16.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":5169,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":5169,"source":{"system":"sec-edgar","filing":"0001193125-26-092074","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092074/ownership.xml","form_type":"4"}},{"id":954882,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-01-02T22:25:52.000Z","date":"2025-12-31","kind":"sale","planned":false,"acquired":false,"shares":2272,"price":31.16,"value":70795.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares purchased under the Issuer's employee stock purchase plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-001097","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526001097/ownership.xml","form_type":"4"}},{"id":1226474,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-05T02:17:03.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":20679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":20679,"derivative":{"underlying":"Common Stock","underlying_shares":20679},"source":{"system":"sec-edgar","filing":"0000950170-25-032908","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017025032908/ownership.xml","form_type":"4"}},{"id":1226473,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-05T02:17:03.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":124072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.  The date of the grant is March 3, 2025."}],"balance_after":124072,"derivative":{"exercise_price":14.41,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":124072},"source":{"system":"sec-edgar","filing":"0000950170-25-032908","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017025032908/ownership.xml","form_type":"4"}},{"id":1642637,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-14T21:05:18.000Z","date":"2024-02-12","kind":"grant","planned":false,"acquired":true,"shares":290000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% on February 12, 2025 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":290000,"derivative":{"exercise_price":19.68,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":290000},"source":{"system":"sec-edgar","filing":"0000950170-24-015205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017024015205/ownership.xml","form_type":"4"}}]}